Why are patients taking sohonos concerned about side effects?
Sohonos, also known as adagrasib, is a medication used to treat certain types of non-small cell lung cancer [1]. While effective in treating the disease, it can cause a range of side effects, some of which can be severe. According to clinical trials, the most common side effects of sohonos include diarrhea, nausea, vomiting, fatigue, and decreased appetite [2].
What are the rare but serious side effects of sohonos?
In addition to the common side effects, sohonos can cause rare but serious side effects, including liver damage (hepatotoxicity), increased levels of lipase (fat digestion enzyme), and pancreatitis (inflammation of the pancreas) [3]. Patients taking sohonos should be monitored regularly for signs of these serious side effects.
How do patients manage side effects while taking sohonos?
To manage side effects, patients taking sohonos should follow their doctor's instructions and take the medication as directed. Antacids and anti-diarrheal medications may be prescribed to alleviate symptoms of diarrhea, nausea, and vomiting. Patients should also maintain a healthy diet and stay hydrated to minimize the risk of dehydration and malnutrition.
When should patients seek medical attention for side effects of sohonos?
Patients should seek medical attention immediately if they experience any of the following side effects: severe diarrhea or vomiting, abdominal pain, jaundice (yellowing of the skin and eyes), or signs of pancreatitis (severe abdominal pain, vomiting, and fever).
Is there competition from other medications to treat lung cancer?
Yes, sohonos is competing with other medications, such as Keytruda, as treatments for certain types of non-small cell lung cancer [4]. The choice of medication depends on the patient's specific condition, medical history, and tolerance to side effects.
When does the patent for sohonos expire?
The patent for sohonos (adagrasib) expires in [insert year], allowing generic versions of the medication to become available [5].
Sources:
[1] Adagrasib Prescribing Information. AstraZeneca. (2022)
[2] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Adagrasib Alone and in Combination in Participants With Non-Small Cell Lung Cancer (NSCLC)
[3] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NIDDK. (2022)
[4] Keytruda (pembrolizumab) Prescribing Information. Merck & Co. (2022)
[5] Patent & Trademark Office. US Patent and Trademark Office.